ALNY Alnylam Pharmaceuticals Inc
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
$143.42 +6.05 (4.40%)
As of 03/05/2021 15:59:56 EST IEX book CBOE book
Security Information
Category1:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
Category2:
Category3:
GICS sector:
Industry:
Index country:
Country of incorporation:
IPO date:
Outstanding shares:
Average volume:
Market cap:
Current dividend yield:
All SEC filings:
Quarterly filings:
Annual filings:
CUSIP:
ISIN:
Sedol:
US Equity
Common stocks
Large cap
Health Care
Biotechnology
USA
USA
05/28/2004
117,002,019
614,361
$16,072,567,350
0.00%
SEC Edgar Online
10-Q
10-K
02043Q107
US02043Q1076
B00FWN1
Common stocks
Large cap
Health Care
Biotechnology
USA
USA
05/28/2004
117,002,019
614,361
$16,072,567,350
0.00%
SEC Edgar Online
10-Q
10-K
02043Q107
US02043Q1076
B00FWN1
Valuation (See tab for details)
PE ratio:
PB ratio:
PS ratio:
Return on equity:
Net income %:
PB ratio:
PS ratio:
Return on equity:
Net income %:
-18.73
15.74
32.61
-84.46%
-174.15%
15.74
32.61
-84.46%
-174.15%